Oral versus intravenous steroids in multiple sclerosis relapses

Abstract

Get full access to this article

View all access options for this article.

References

Miller

Newell

Ridley

. Multiple sclerosis: Treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; 2: 1120–1122.

Citterio

La Mantia

Ciucci

. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; 4: CD001331.

Sydes

Langley

. Potential pitfalls in the design and reporting of clinical trials. Lancet Oncol 2012; 11: 694–700.

Miller

Weinstock-Guttman

Bethoux

. A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler 2000; 6: 267–273.

Barnes

Hughes

Morris

. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902–906.

Ramo-Tello

Grau-Lopez

Tintore

. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014; 20: 717–725.

Burton

O’Connor

Hohol

. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12: CD006921.

Groenewoud

Hundt

Luus

. Absolute bioavailability of a new high dose methylprednisolone tablet formulation. Int J Clin Pharmacol Ther 1994; 32: 652–654.

Hayball

Cosh

Ahern

. High dose oral methylprednisolone in patients with rheumatoid arthritis: Pharmacokinetics and clinical response. Eur J Clin Pharmacol 1992; 42: 85–88.

10.

Lublin

Baier

Cutter

. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–1532.

Oral versus intravenous steroids in multiple sclerosis relapses – a perennial question?

Abstract

Get full access to this article

References